Eric Wehrenberg-Klee,Lipika Goyal
Eric Wehrenberg-Klee
A step towards informed positioning of advanced therapies for moderate-to-severe Crohn's disease [0.03%]
走向对中度至重度克罗恩病的先进疗法的明智定位一步
Waseem Ahmed,Dana J Lukin
Waseem Ahmed
Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial [0.03%]
特瑞普利单抗联合或不联合塞来昔布新辅助治疗错配修复缺陷或微卫星高度不稳定局部晚期结直肠癌（PICC）：一项单中心、平行分组、非对照随机二期临床试验
Huabin Hu,Liang Kang,Jianwei Zhang et al.
Huabin Hu et al.
Background: PD-1 blockade is highly effective in patients with mismatch repair-deficient or microsatellite instability-high metastatic colorectal cancer. The role of single-agent PD-1 blockade in the neoadjuvant setting f...
Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis [0.03%]
生物制剂治疗中重度克罗恩病的疗效和安全性的比较：系统评价与网络Meta分析
Siddharth Singh,M Hassan Murad,Mathurin Fumery et al.
Siddharth Singh et al.
Background: Data are needed to inform the positioning of biologic therapy in the treatment of moderate-to-severe Crohn's disease, both first line and after previous biologic exposure. We aimed to assess the comparative ef...
Thierry André,Romain Cohen
Thierry André
SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy [0.03%]
接受生物制剂治疗的炎症性肠病患者对SARS-Cov-2疫苗的接种情况
Rania Selim,Judith Wellens,Luke Marlow et al.
Rania Selim et al.
Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease [0.03%]
免疫抑制的炎症性肠病患者中的SARS-COV-2疫苗第三剂接种
James L Alexander,Christian P Selinger,Nick Powell;British Society of Gastroenterology Inflammatory Bowel Disease section and the Inflammatory Bowel Disease Clinical Research Group
James L Alexander
Philip Berry,Mark MacDonald,Sreelakshmi Kotha
Philip Berry